CORRECTION Open Access

Check for updates

Correction to: The aluminium-[18F]fuoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules

Stephen J. Archibald 1,2,3 and Louis Allott 1,2,3*

The original article can be found online at https://doi.org/10.1186/s41181-021-00141-0.

*Correspondence: louis.allott@hull.ac.uk
¹ Positron Emission
Tomography Research
Centre, Faculty of Health
Sciences, University of Hull,
Cottingham Road, Kingston
upon Hull HU6 7RX, UK
Full list of author information
is available at the end of the

Correction to: EJNMMI Radiopharm. Chem. (2021) 6:30

https://doi.org/10.1186/s41181-021-00141-0

Following publication of the original article (Archibald and Allott 2021), the authors identified an error in Table 2 and Fig. 3. The correct table and figure are given below.

The original article (Archibald and Allott 2021) has been corrected.

Table 2 Prominent examples of [18F]AIF radioconjugates discussed in this review

Кеу:	Non-decay Corrected (n.d.c.) Decay Corrected (d.c.) d.c. on n.d.c. not disclosed Not Reported Reported				Automated	Clinical Trial	
Target	[¹⁸ F]AIF Radioconjugate	Starting [18F]F (GBq)	RCY (%)	A _m (GBq/μmol)	Autor	Clinic	Ref
SSTR	[18F]AIF-NOTA-octreotide	41 - 42	26.1 ± 3.6	160.5 ± 75.3	Υ	Υ	(Allott et al., 2017; Hou et al., 2020; Long e
PSMA	[¹8FIAIF-PSMA-11	18.5 - 100	15 – 24	58 – 544	Y	Y	al., 2019; Tshibangu et al., 2020) (Giglio et al., 2018; Kersemans et al., 2018
	[18F]AIF-PSMA-BCH	2.20 - 4.40	32.2 ± 4.5	13.2 – 18.9	N	Ý	(Liu et al., 2019)
	[18F]AIF-NOTA(5)-DUPA-Pep	0.87	79	3.4	N	N	(Malik et al., 2012)
	[18F]AIF-Glu-urea-Lys(Ahx)L3	40	25	27.0	Y	N	(Cleeren et al., 2016)
	[18F]AIF-P16-093	0.37	54.4 ± 4.4	-	N	N	(Zha et al., 2021)
GZB	[18F]AIF-mNOTA-GZP	10	17 - 25	45 - 90	N	N	(Goggi et al., 2020)
PD-L1	[18F]AIF-NOTA-ZPD-L1 1		15.1 ± 5.6	14.6 ± 6.5	N	N	(González Trotter et al., 2017)
		50	1011 - 111				
IL2R	[18F]AIF-RESCA-IL2		2.4 ± 1.6	910 ± 927	N	N	(van der Veen et al., 2020)
FAP	[18F]AIF-NOTA-FAPI-74	2 - 10	-	20 - 50 49.4 ± 3.2	Y	Y	(Giesel et al., 2021)
	[¹⁸ F]AIF-NOTA-FAPI-04 [¹⁸ F]AIF-NOTA-Z _{HER2-2395}	32 - 37 2 - 6	26.4 ± 1.5 21.0 ± 5.7	7.7 ± 3.0	N	N	(Jiang et al., 2021) (Heskamp et al., 2012)
HER2	[18F]AIF-NOTA-MAL-MZHER2:342	3.70	10	7.7 ± 3.0	N	N	(Xu et al., 2017)
	[18F]AIF-NOTA-WAL-WZHER2:342	0.12	11 ± 4	0.35	N	N	(Glaser et al., 2017)
	[18FIAIF-NOTA-ZHER22891	0.25 - 0.30	9.9 – 27.4	6.0 – 11.9	N	N	(Da Pieve et al., 2016)
HER3	[18F]AIF-NODA-ZHER3:8698	0.46 - 0.50	9.9 – 27.4	5.5 – 18.4	N	N	(Da Pieve et al., 2016)
EGFR	[18F]AIF-NOTA-ZEGFR:1907	37	15	1.5	N	N	(Su et al., 2014)
	[18F]AIF-NOTA-PODS-ZegfR:03115	0.18 - 0.20	11.0 - 12.7	3.0 – 4.4	N	N	(Da Pieve et al., 2020)
	[18F]AIF-NODAGA-PODS-Zegfr.03115	0.18 - 0.20	4.3 – 8.1	0.8 – 1.7	N	N	(Da Pieve et al., 2020)
Integrins	[18F]AIF-NOTA-RGD2	0.55	17.9	11.1 – 14.7	N	N	(Liu et al., 2011)
	[18FIAIF-NOTA-PRGD2	0.37 - 1.50	20 - 25	6.14	N	Y	(Lang et al., 2011; Wan et al., 2013; Zhou
							al., 2017)
	[18F]AIF-PEG ₂₈ -A20FMDV2	11	19.3 ± 5.4	0.8 ± 0.2	N	N	
	[18F]AIF-NODAGA-E[c(RGDfK)] ₂	2 - 6 0.37 - 0.74	20 40 - 60	1.8 14.8 - 37	N	N	(Dijkgraaf et al., 2013)
	[¹⁸ F]AIF-NOTA-PEG ₄ -E[c(RGDfK)] ₂					N	(Guo et al., 2014) (Guo et al., 2014)(Wu et al., 2018; Yu et al
	[18F]AIF-NOTA-E[PEG ₄ -c(RGDfK)] ₂	0.37 - 0.74	40 - 60	14.8 - 37	N	Y	2015)
	[18F]AIF-NOTA-E[c(RGDfK)] ₂	0.37 - 0.74	40 - 60	14.8 - 37	N	N	(Guo et al., 2014)
GRPR	[18F]AIF-NODAGA-RM1	0.55	5.9 ± 1.1	1.85	N	N	(Liu et al., 2013)
	[18F]AIF-NODAGA-AMBA	0.55	4.9 ± 1.3	1.85	N	N	(Liu et al., 2013)
	[18F]AIF-NOTA-8-Aoc-BBN(7-14)NH ₂	1.10 - 3.30	50	10	N	N	(Dijkgraaf et al., 2012)
	[18F]AIF-NOTA-4,7-lanthionine-BBN	0.20 - 0.32	50 – 60	63	N	N	(Carlucci et al., 2015)
	[18F]AIF-NOTA-2,6-lanthionine-BBN	0.20 - 0.32	50 - 60	88	N	N	(Carlucci et al., 2015)
	[18F]AIF-NOTA(6)-MATBBN	1.11	62.5 ± 2.1	30	N	N	
	[¹⁸ F]AIF-JMV5132	0.70 - 0.90	88	40 ± 4	N	N	(Chatalic et al., 2014)
CXCR4	[¹⁸ F]AIF-NOTA-P2-RM26	1-2	60 - 65	55	N	N	(Varasteh et al., 2013)
	[¹⁸ F]AIF-NOTA-pentixather	-	45.5 ± 13.3	≤24.8	N	N	(Poschenrieder et al., 2016)
	[18F]AIF-NODA-NCS-pentixather	0.05 4.04	45.5 ± 13.3	≤24.8	N	N	(Poschenrieder et al., 2016)
	[18F]AIF-NOTA-T140	0.85 - 1.04	58.0 ± 5.3	18.9 ± 1.1	N	N	(Yan et al., 2016)



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.




Fig. 3 Structures of chelators evaluated for [18F]AIF and their proposed complexes. R = bioconjugation handle. 3D models were created in ChemBio3D (Cambridgesoft, UK) with MM2 energy minimization applied. Atom colours: carbon = light grey, hydrogen = white, oxygen = red, nitrogen = blue, fuorine = yellow, aluminium = dark grey. RT = room temperature. *Optional 1:1 (v/v) co-solvent included in the reaction mixture to improve RCY

Author details

¹Positron Emission Tomography Research Centre, Faculty of Health Sciences, University of Hull, Cottingham Road, Kingston upon Hull HU6 7RX, UK. ²Department of Biomedical Sciences, Faculty of Health Sciences, University of Hull, Cottingham Road, Kingston upon Hull HU6 7RX, UK. ³Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ, UK.

Published online: 24 September 2021

Reference

Archibald and Allott EJNMMI Radiopharm. Chem. (2021) 6:30 https://doi.org/10.1186/s41181-021-00141-0

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.